Advances in Bioinspired Artificial System Enabling Biomarker‐Driven Therapy

Abstract

Bioinspired molecular engineering strategies have emerged as powerful tools that significantly enhance the development of novel therapeutics, improving efficacy, specificity, and safety in disease treatment. Recent advancements have focused on identifying and utilizing disease‐associated biomarkers to optimize drug activity and address challenges inherent in traditional therapeutics, such as frequent drug administrations, poor patient adherence, and increased risk of adverse effects. In this review, we provide a comprehensive overview of the latest developments in bioinspired artificial systems (BAS) that use molecular engineering to tailor therapeutic responses to drugs in the presence of disease‐specific biomarkers. We examine the transition from open‐loop systems, which rely on external cues, to closed‐loop feedback systems capable of autonomous self‐regulation in response to disease‐associated biomarkers. We detail various BAS modalities designed to achieve biomarker‐driven therapy, including activatable prodrug molecules, smart drug delivery platforms, autonomous artificial cells, and synthetic receptor‐based cell therapies, elucidating their operational principles and practical in vivo applications. Finally, we discuss the current challenges and future perspectives in the advancement of BAS‐enabled technology and envision that ongoing advancements toward more programmable and customizable BAS‐based therapeutics will significantly enhance precision medicine.